The recent CMS moratorium on new enrollments for DMEPOS suppliers effective as of February 27, 2026, has brought renewed industry focus on supplier locations.

When DME suppliers encounter an arrangement that promises unusually fast profits or earnings far above historical norms, it is often a warning sign.

A company that has been correctly served with a valid subpoena usually must act. Note that the company needs to “act,” not necessarily to “respond.”

Matt Filippis will serve as VGM's new director of Business Development for Clinical Mobility and Accessibility.

If DME suppliers violate federal laws, it will likely come to the attention of the federal government.

CatTongue Grips gained traction at Medtrade as providers discovered non-slip solutions that could help older adults.